Jackofalltrade5
Posted - 3 days ago
$TCRX 🤬
soll
Posted - 6 days ago
$TCRX
soll
Posted - 1 week ago
$TCRX Per Morgan Stanley: Justin Zelin BTIG Buy 11/12/24 $12.00 Justin Zelin is a Director and BTIG Biotechnology Analyst, specializing in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics. Prior to BTIG, Mr. Zelin was a Biotech Equity Research Analyst at B. Riley Securities. Previously, he held biotech equity research associate roles at Canaccord Genuity and SVB Leerink. Earlier in his career, Mr. Zelin worked in both academic and industry labs including Agenus, Harvard University and Brigham and Women’s Hospital. He was also a member of Harvard University’s teaching staff for more than five years. Mr. Zelin earned a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University.
soll
Posted - 1 week ago
$TCRX per Morgan Stanley: Sam Slutsky LifeSci Capital Buy 11/12/24 $12.00
soll
Posted - 1 week ago
$TCRX TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update November 12, 2024 Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10th at 8:00 a.m. ET to discuss clinical updates from the ALLOHA Phase 1 trial and heme development strategy On track to dose first patient with multiplex TCR-T therapy and will provide an update on our Phase 1 study by the end of the year Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-reports-third-quarter-2024-financial-results
DonCorleone77
Posted - 1 week ago
$TCRX TScan Therapeutics reports Q3 EPS (25c), consensus (29c) Reports Q3 revenue $1.049M, consensus $1.06M. "As we approach the end of the year, we remain committed to advancing our clinical-stage pipeline across both heme and solid tumor malignancies and providing an update on the ALLOHA Phase 1 trial following ASH. We are encouraged to see that none of the 16 patients on the treatment arm relapsed, including five patients at least one-year post-transplant as of the July 8th abstract cutoff date. We look forward to sharing updated data, including several additional patients, at ASH," said Gavin MacBeath, Ph.D., Chief Executive Officer. "During the third quarter we continued to prioritize screening, enrolling, and dosing patients in the solid tumor program and remain on track to dose our first patient with multiplex therapy and provide an update on our Phase 1 study by the end of the year."
soll
Posted - 1 week ago
$TCRX Bowman, et al. Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity. SITC 2024 https://tscan.com/wp-content/uploads/2024/11/Preclinical-Models-for-T-Plex-a-Customized-Multiplexed-TCR-T-Cell-Therapy.pdf
soll
Posted - 1 week ago
$TCRX Kulkarni, et al. Discovery of a MAGE-A4-specific TCR-T therapy candidate for multiplex treatment of solid tumors. SITC 2024 https://tscan.com/wp-content/uploads/2024/11/TSC-202-A0201-SITC.pdf
soll
Posted - 1 week ago
$TCRX Padmanabhan, et al. Development of a target agnostic platform to assess the reactivity of T cell receptor (TCR)-engineered T cell (TCR-T) therapies to primary human tissues. SITC 2024 https://tscan.com/wp-content/uploads/2024/11/2024_SITC-SafeScan.pdf
soll
Posted - 1 week ago
$TCRX November 8, 2024 A Form SC 13G has been filed with the United States Securities and Exchange Commission. https://ir.tscan.com/static-files/1f4d0a66-ebdb-45a8-8620-615a4c6dbd60
StreetwiseReports
Posted - 2 weeks ago
New Blood Cancer Treatment Shows Continued Response: https://ow.ly/nlq050U2z6I The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report. $TCRX #biotechstocks #celltherapy TScan Therapeutics Inc.
RallyRaider
Posted - 2 weeks ago
$TCRX move on air..... no veto
Stocks4thought
Posted - 2 weeks ago
$BWAY We told you below- new girls $SGMT $TCRX you get it$
soll
Posted - 2 weeks ago
$TCRX per: Morgan Stanley Sam Slutsky LifeSci Capital Buy 11/05/24 $12.00
soll
Posted - 2 weeks ago
$TCRX 66th ASH Annual Meeting TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial Result Type: Paper Number: 924 Presenter: MHD Monzr Al Malki Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies Time and Location: Monday, December 9, 2024: 2:45 PM-4:15 PM Hall B (San Diego Convention Center) Search Result: ... or HA-1/HA-2, TSC-100 and TSC-101 can eliminate residual patient hematopoietic cells post-HCT while sparing donor-derived cells, thereby preventing relapse. The ALLOHA Study (TSCAN-001, NCT05473910) is a multi-center, biologically controlled, Phase 1 study evaluating TSC-100 and TSC-101 in adults with AML, ALL ... https://ash.confex.com/ash/2024/webprogram/start.html#srch=words%7CALLOHA%7Cmethod%7Cand%7Cpge%7C1%7CbyDayany%7Cany%7CbySymposiumany%7Cany%7CbyAudienceany%7Cany
soll
Posted - 2 weeks ago
$TCRX All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m. ET https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-announces-upcoming-oral-presentation-data
soll
Posted - 2 weeks ago
$TCRX
